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ABSTRACT

PREDICTING ALZHEIMER DISEASE STATUS USING
HIGH-DIMENSIONAL MRI DATA BASED ON LASSO
CONSTRAINED GENERALIZED LINEAR MODELS
BY

ZAINAB SALAH
MAY 22, 2017
INTRODUCTION: Alzheimer’s disease is an irreversible brain disorder characterized by distortion of
memory and other mental functions. Although, several psychometric tests are available for diagnosis of
Alzheimer’s, there is a great concern about the validity of these tests at recognizing the early onset of the
disease. Currently, brain magnetic resonance imaging is not commonly utilized in the diagnosis of
Alzheimer’s, because researchers are still puzzled by the association of brain regions with the disease
status and its progress. Moreover, MRI data tend to be of high dimensional nature requiring advanced
statistical methods to accurately analyze them. In the past decade, the application of Least Absolute
Shrinkage and Selection Operator (LASSO) has become increasingly popular in the analysis of high
dimensional data. With LASSO, only a small number of the regression coefficients are believed to have a
non-zero value, and therefore allowed to enter the model; other coefficients are while others are shrunk to
zero.
AIM: Determine the non-zero regression coefficients in models predicting patients’ classification
(Normal, mild cognitive impairment (MCI), or Alzheimer’s) using both non-ordinal and ordinal LASSO.
METHODS: Pre-processed high dimensional MRI data of the Alzheimer’s Disease Neuroimaging
Initiative was analyzed. Predictors of the following model were differentiated: Alzheimer’s vs. normal,
Alzheimer’s vs. normal and MCI, Alzheimer’s and MCI vs. Normal. Cross-validation followed by ordinal
LASSO was executed on these same sets of models.
RESULTS: Results were inconclusive. Two brain regions, frontal lobe and putamen, appeared more
frequently in the models than any other region. Non-ordinal multinomial models performed better than
ordinal multinomial models with higher accuracy, sensitivity, and specificity rates. It was determined that
majority of the models were best suited to predict MCI status than the other two statues.
DISCUSSION: In future research, the other stages of the disease, different statistical analysis methods,
such as elastic net, and larger samples sizes should be explored when using brain MRI for Alzheimer’s
disease classification.
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1. INTRODUCTION
1.1 CURRENT STATISTICS OF ALZHEIMER’S DISEASE:
Alzheimer’s disease is the most common form of dementia among adults age 65 and
above. It’s ranked the sixth leading cause of death in the United States, causing more deaths than
both breast and prostate cancer combined [1]. According to Alzheimer’s Association and
Alzheimer’s Disease International, over 5 million American [1] and around 47 million
worldwide [2] seniors are diagnosed with Alzheimer’s or other forms of dementia. And while
only 1 in every 10 seniors is believed to have some form of dementia in the United States, 1 in
every three is thought to be terminal with either Alzheimer’s or dementia [1]. These statistics
may appear startling, but they are expected to rise in the near future as the population of older
adults is rapidly increasing. Dementia, including Alzheimer’s, has a severe impact on the
nation’s health care system and worldwide economy. It is believed that the burden of these brain
disorders will cost over quarter of trillion dollars for the United States alone [1].
Alzheimer’s disease was first discovered by German psychiatrist Alois Alzheimer in the
early 20th century and was named after him [3,4]. In his research, Alzheimer noticed distinctive
plaques in the brain histology of deceased women. He discovered that this woman had died of an
unknown mental illness after studying her for five years [4]. The main noted symptoms of the
disease included loss of cognitive functioning, namely thinking, remembering, reasoning, and a
loss of behavioral abilities, which hindered a person’s ability to accomplish activities of daily
living [3]. Today, this irreversible disease is known to progress over time by destroying memory
cells in the brain and results in memory decline, and notably deteriorated mental functioning.
The current Alzheimer’s treatments are incapable of stopping the progress of this disease and
continue to baffle healthcare providers and researchers. Current scholarship is dedicated to
1

designing treatment which will slow down the process of the disease in order to improve lives of
all those severely impacted by the disease [1]. Now more than ever it is pivotal to understand the
stages of this disease and develop clear scheme of how to predict and detect its prevalence as
early as possible.
1.2 STAGES OF THE DISEASE:
In order to understand the disease one must first understand the physiology of the brain.
Human brains start shrinking as they begin to age. In this aging process a human brain also
begins to lose weight. In Alzheimer’s patients, an aging adult brain not only shrinks but also
begins to develop knots. These knots are due to twisted protein fibers which release chemicals,
damaging the nerve cells in the brain [5]. Although these chemicals alter the brain silently, they
are lethal. Within a few years Alzheimer’s symptoms are evident. The disease progresses from
mild to moderate to severe cognitive impairment [1]. Currently, there are no definite molecular
pathways used to define these specific stages. There are no reliable biomarkers used to diagnose
the early stages of this disease. Many factors have been hypothetically attributed to the onset of
Alzheimer’s which include: age, genetics, dysfunctional immune system, and infectious disease
[6]. Researchers are systematically attempting to validate these hypotheses by also examining the
progression of the disease from normal to mild cognitive impairment to Alzheimer’s patients
[1,2], with the hope of developing effective drugs and therapies to slow the progression of the
disease.
1.3 CLINICAL DIAGNOSIS:
Physicians depends the knowledge of family member’s when consulting a new patient
regarding his/her overall health. Tests such as: memory retention, problem solving, counting,
attention, and language tests are used, and immediately by blood and urine tests, and magnetic
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resonance imaging (MRI) scans or positron emission tomography (PET) scans [3]. While the
neurological tests are useful tools in distinguishing demented from non-demented seniors, they
lack the ability to detect early signs of cognitive impairment or the current stage or progression
of the disease. At times, these assessments may also fail to detect the problems the patient is
experiencing and completely misdiagnose the main health issue [8]. At this time there are no
known and standardized biomarkers used to detect the early signs of Alzheimer’s disease other
than post-mortem brain histological examinations [2,3]. Therefore, conducting brain scans are
only useful methods which should be used to rule out the possibility of other diseases, and not to
diagnose Alzheimer’s disease. Current research focuses on diagnostic biomarkers based on brain
regions, cerebrospinal fluid, and blood content [3,8].
1.4 REGIONS OF INTEREST:
Several researchers have conducted studies [9-10, 12-13, 17-19] using the ADNI
database in hopes of finding regions of interest (ROI) in the brain which should be the most
predictive of early onset dementia, while others researchers considered regions related to
conversion from normal to mild cognitive impairment (MCI), normal to Alzheimer’s (AD),
and/or MCI to AD. Other studies recruited volunteer participants of memory centers in Germany
[11, 16] and in France [14]. The following ROI were cited in the above studies: left entorhinal
cortex [10], left and/or right hippocampus [10,12,14,16,18, 19], parahippocampus [16], frontal
lobe [11, 16, 18], temporal lobe [11, 16, 17, 18, 19], right inferior [12], parietal lobule [12, 14],
anterior cingulate [12], amygdala [18, 15, 17], and occipital [14]. Other studies had contradictory
finding regarding the association of frontal and parietal lobe with disease classification [13],
there two regions were found be insignificant predictors of the disease classification.
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Classification of MCI were best achieved by inclusion of amygdala and hippocampus in
the model [13, 16, 17], while inclusion of ganglia and insula were insignificant for both MCI and
AD [11]. Classification accuracy rates were reported from most of the above literatures, which
ranged from 85% to 95%, with highest accuracy rate reported with grey matter region included.
For MCI classification, accuracy rates were lower ranging from 70% to low 90’s%.
Classification accuracy rates seemed to be lower for studies that used smaller sample sizes.
No associations were found between Alzheimer’s disease with age or gender [10,11,20].
However, statistics of the disease suggests otherwise; women are twice as likely to be diagnosed
with dementia when compared to the number of men diagnosed with dementia. A review of the
current research suggests one explanation for women having higher likeligood of being
diagnosed: it is believed than men are more ikely to die from competing causes, such as auto
accidents, gun violence, etc., which women are less likely to encounter [21]. Studies have also
suggested an insignificant association between the disease and other demographic parameters
such as race, educational level, and economical factors [20]. Based on these findings from
previous studies and the time constraint of this study, gender, age, and demographic factors were
excluded from our study.
1.5 ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE:
The data used for this study is from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI), which is comprised of images collected by scientists of both health and cognitively
impaired adult brains to develop biomarkers for tracking disease progression. ADNI, which
funded by the National Institute of Health, collects demographic, clinical, neuroimaging, genetic,
as well as biospecimens data from volunteer participants [22]. Researchers from around the
world may access the data upon registration. Seven clinics in the United States and Canada
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currently contribute to these frequently updated data archive. The initiative consists of three
cohorts of data participants: ADNI started in 2004 and followed participants for 5 years, ADNIGO started in 2009 and followed participants for two years, and ADNI2 started in 2011 with a
follow-up period of 5 years. Recently, ADNI began its fourth phase called, ADNI3 which began
in September of 2016 [22].

2. A SUMMARY OF THE STATISTICAL METHOD
2.1 ORDINARY LEAST SQUARE REGRESSION:
In the basic regression, or ordinary least square (OLS) regression, a response variable is
graphed against an explanatory variable, where the variability in the later explains the variability
of the former. A linear curve is then fit through the data points. This linear curve quantitatively
minimizes the sum of the square error and hence the nomenclature of Best Linear Unbiased
Estimator (BLUE) [25, 28, 30].
.

𝑚𝑚𝑚𝑚𝑚𝑚
2
→ || 𝑦𝑦⃗ - x𝛽𝛽⃗ || 2
𝛽𝛽

(1)

OLS performs well when the number of variables in the models (x’s) is small. However, as the
number of variables increase, the possibility of correlation between these variables increases as
well, which in turn upsurges the variance of the βs both drastically and erroneously
[23,24,26,29]. Therefore, it seems plausible to introduce a constraining term to minimize how
large a β can approach [24].
2.2 REGULARIZATION AND PENALTY:
There are several forms of regularization, such as forward and backward selection, bestsubset, ridge regression, and LASSO [24,25,27]. In forward selection, features are added one at a
time and stop only when an overfitting is detected. In backward selection, features are
5

permanently removed one at a time so long as they are insignificant. However, a dropped feature
at an earlier step could be significant when added to the final reduced model. Best-subset
selection finds the set of variables that fits the data the best. There feature selection methods are
optimal when the number of variables is small [24,26,29]. Ridge regression and LASSO
regression are best suited for high dimensional data [23,24,30]. Both methods use a form of
penalty to limit the number of variables entering the model.
Many constraining or penalty terms have been researched, but perhaps the two most well
know ones are the L1 and L2 norm, with L2 norm being more commonly used than L1 norm
[25,28]. Both L1 and L2 serve the same purpose, which is to limit the size of the βs to control the
erroneous variation caused by their correlation. Both the L1 and L2 end up constructing around
the center of the origin. The main difference between the two is the geometric shape of the
constraint. Typically, the L2 norm is circular and the L1 norm is square [25,28,29]. The square
shape constraint of the L1 norm shrinks many βs to exactly zero, reducing the number of nonzero coefficients [23,24,30]. This advantageous property of L1 norm is termed feature selection,
because it allows the model to select only feature or variables that have true impact on the
response [23,24,27]. LASSO developed by Tibshirani in 1996 utilizes L1 norm [23-30].
2.3 LEAST ABSOLUTE SHRINKAGE AND SELECTION OPERATOR:
In LASSO, the goal is to minimize the sum of the square error, but within a constraining
limit.
𝑚𝑚𝑚𝑚𝑚𝑚
2
1
→ || 𝑦𝑦⃗ - x𝛽𝛽⃗ || 2 + λ || 𝛽𝛽⃗ || 1
𝛽𝛽

(2)

Where λ is the shrinkage estimator or the tuning parameter, which controls the strength of the
constraint. It takes any value greater than zero (λ > 0). When λ is close to zero, equation (2) is
equal to equation (1), or LASSO would produce similar parameter estimates as OLS. On the
6

other hand, when λ is large, then more parameter estimates approach a minimal value or zero and
are therefore removed from the model [23,24,28-30]. In practice, several λs are used to calculate
an array of parameters, and the right choice of λ should ultimately reduce the square error
[23,26,29]. This however, does come at a price. The generated estimates are not unbiased but
have reduced variance. Consequently, if the βs are all large relative to their variances, a small
value of λ is selected, whereas if several β’s in the model are small, a large λ is preferred to pull
these parameters close to zero [24,25,29].
Similarly, a regularization term may also be added to a model with discrete outcome to
avoid overfitting using the following model;
𝑚𝑚𝑚𝑚𝑚𝑚
1
→ – 2 ln 𝛽𝛽⃗ + λ || 𝛽𝛽⃗ || 1
𝛽𝛽

(3)

Where if lambda is set too high an underfitting will occur, and if set too low, close to zero, the
generated estimates will approximate the unpenalized logistic regression estimates.

3. METHODS
3.1 DATA:
For this study, ADNI UA-MRI SPM VBM [22] imaging data, and ADNI DXSUM
PDXCONV ADNIALL [22] diagnosis data were merged using the unique identifier variable
(ID). Both datasets were accessed and downloaded on February 15, 2017 (permission granted in
January 7, 2017). Only images for the 6-month follow-up visit were included. Unrelated MRI
imaging variables, such as image quality and different diagnosis statuses and conversions, were
excluded, and only participants with known clinical diagnosis were included. The Final dataset
included 136 variables excluding the response variables (diagnosis), and 343 observations.

7

3.2 STATISTICAL MODELS:
For this study three disease classifications (diagnoses) were considered: normal
(control), mild cognitive impairment (MCI), and clinically diagnosed with Alzheimer’s disease
(AD). Initially, we only examined prediction models with binomial responses, which included
only Alzheimer’s and the control individual. To check whether MCI’s MRIs were more to the
control group or AD group, additional binomial models were fitted by either combining MCI
with the control group or with the AD group. Following the binomial models, a multinomial
model was fitted using the three disease classes as the dependent variable. Both ungrouped and
grouped multinomial models were analyzed. The ungrouped models allowed different predictors
with different response values, while grouped models were considered either all-in or all-out
models. In other words, a predictor is either applicable for all three disease classifications or left
out of the model entirely.
To estimate the prediction, cross validation was carried out on these models. Finally, to
account for the ordering characteristic of our dependent variable, the data was fitted in an ordinal
multinomial logistic regression model. All models were induced with LASSO penalty.
3.3 STATISTICAL PACKAGES:
Data were merged using SAS 9.3 software [31]. The same software was also used to
generate the demographic statistics. The remaining statistical analysis were performed in R [32]
using mainly two packages for non-ordinal and ordinal LASSO logistic regression, respectively.
The first package was glmnet package [33] with glmnet () function for model fitting, predict ()
function for coefficient prediction, and cv.glmnet () for cross validation [34]. The second
package was glmnetcr package [35] with glmnet.cr () function for ordinal logistic modeling
fitting, and nonzero.glmnet.cr () for displaying non-zero coefficients [36].
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4. RESULTS AND DISCUSSION
4.1 DATASET:
In this study, the task was to predict the diagnosis status of individuals in the selected
ADNI study dataset based on a spectrum of MRI data. A total of 343 individuals’ MRI were
examined within a data matrix containing 174 total number variables. The number of covariates
considered large rendering it a good candidate for LASSO regression model fitting technique.
Lasso allows for penalized regression techniques that are flexible enough for high-dimensional
data and can be applied directly without the need of dimension reduction [23-30]
The dataset was examined and variables not related to MRI imaging, which included
image quality parameters, several recoded diagnoses, recoded date of visits, and several subject
identifications, were excluded. The final data set included 83 AD, 146 MCI, and 114 control
individuals with total of 137 predictors (see Appendix A for detailed list of predictors). Number
of predictors included in the models, subsequent to model convergence was 109 for the AD vs
control. While number of predictors entered in the model, after model convergence, was 117 for
the AD vs. MCI&normal, AD&MCI vs. normal, and the multinomial models.
4.2 DEMOGRAPHICS:
The overall mean age of the participants in the sample was 72.1 (±6.7). Majority of the
sample have college degrees. Males composed about 58% of the sample, and the rest were
female seniors. Majority of the sample were married (74.3%). The rest were either widowed,
divorced, never married, or with unknown marital statuses, 15%, 7%, 3.2%, and 1%,
respectively. Majority of the participants were retired (84.0%), and only a small fraction of them
were currently working (9.9%). Finally English was the primary language of the participants
(98.3%). Detail demographic statistics appear in Table 1.
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4.3 LASSO MODEL FITTING:
The coefficients for the converged model predictors were plotted against two different
scales: the fraction deviance explained, and the L1 norm for each set of comparison (Figure 1-4).
In these plots, each curve represents a coefficient in the model. In these plots, each colored line
summarizes the path of a different coefficient in the model [33-34]. Lambda is used as the
regularization term, and thus as lambda decreased or approaches zero, the more coefficients enter
the model, and the model approaches the OLS solution in which all coefficients are allowed in
the model. Likewise, when lambda is allowed to increased, the regularization term is allowed to
have a greater effect by allowing as few variables into the model, leaving more coefficients with
a zero value. While variables that enter the model early on are considered the most predictive of
the outcome of interest, the variables that enter the model later are less predictive. In other
words, the predictors go into the model in the order of their magnitude of predictive effect. As
predictors enter into the model, the slope of the coefficient path of their predictors already in the
model is affected [33-34].
The performance of LASSO algorithm was then analyzed by examining the specificity,
sensitivity, and the accuracy rates of prediction using several lambda values. The results for the
specificity, sensitivity, and accuracy rates are summarized in Figure 6. As the lambda values
increased, the accuracy of the model simultaneously decreased. At smaller lambda values when
no regularization term was added to the model and all predictors were in the model, the
sensitivity was found to be zero, with specificity at its peak at 100%, with accuracy fluctuation
between the models. As the lambda values increased, and on average all models’ accuracies rates
decreased, some of the models did outperform others under different lambda values. For
instance, while the accuracy rates for the binomial models were low 70% at λ10, the multinomial
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models were barely over 50% at the same lambda size. Furthermore, the AD vs. control model
outperformed all model at low lambda values.
4.4 CROSS VALIDATION:
Cross validation is a useful technique that estimates prediction error of a model. In
principle, once a model is fitted, it is trained on an external sample to determine the accuracy of
the prediction. However, practically, cross-validation is accomplished by splitting the data into K
sets, and a model is fitted using one of the sets and then trained on the rest. Hence, the
nomenclature K-fold cross-validation [37]. For this study, 10-fold cross-validation was carried to
choose the tuning parameter, λ, with the smallest prediction error. Figures 7-11 depict the crossvalidated error curves for binomial (AD vs. Control, AD&MCI vs. Control, AD vs.
MCI&Control), multinomial, and grouped multinomial logistic regression models. All model
generated similar lambda min, 𝜆𝜆𝑚𝑚𝑚𝑚𝑚𝑚 , and lambda plus 1 standard error, 𝜆𝜆1𝑠𝑠𝑠𝑠 , values, except for
the multinomial model.

4.5 MODEL COEFFICIENTS:
The multinomial model was the only model that the contained non-zero coefficients
(Table 2). Non-zero coefficients for different lambda values were determined based on the
different models (Table 3). The results suggested an unstable prediction error for all the models
except for the Grouped-Multinomial models and possibly for the binomial AD&MCI vs. Control.
When different lambda values were trained, the number of coefficients increased as the lambda
value increased (Table 3). The results fluctuated with a high level of uncertainty. In certain brain
regions there seemed to be an association with disease classification regardless of lambda values.
For instance, putamen appeared in many of the models and in all lambda values. However, for
the multinomial models, different brain regions appeared to be associated with different disease
11

classification. When the grouped multinomial logistic regression is applied, frontal lube and
putamen appear to have the most effect on disease classification.
Based on the prediction error curves the following values of lambda seemed to generate
the least mean prediction error: binomial model (AD&MCI vs. Control) s = 0.3-0.07, binomial
model (AD vs. MCI&Control), s = 0.015-0.3, and grouped-multinomial s = 0.02. The lambda
values were used to determine the coefficients most predictive of disease classification (Table 4).
Disease classification seemed to be related to different brain regions depending on classification
criteria. When AD is combined with MCI and compared to control individuals, frontal lobe and
supplementary motor, and vermis regions are the best predictors. On the other hand, when AD is
compared to the combined MCI and control individuals, many regions are included in the model
which suggested ambiguity of this type of classification. This is also true when classification is
done on grouped level multinomial.
Frontal lobe was found to be one of the ROI in earlier studies of Alzheimer’s disease [3,
16, 18], whereas the vermis, supplementary motor, or putamen region were not cited in previous
literature as one of the ROI. Other cited ROI such as hippocampus [10, 2, 4, 6, 8,19] did not
appear in any of the model as good predictor of disease classification. Amygdala [15,18, 9] was
only good predictor in the grouped-multinomial model. Temporal lobe [10,16,17,18,19]
predicted disease classification only at small tuning parameter values for the binomial AD vs.
MCI&Control and grouped-multinomial models. Parietal lobe [12,14] also, only predicted at
small lambda values, binomial AD&MCI vs. Control and grouped-multinomial models.
4.6 ORDINAL LASSO
Dementia progresses though several stages of cognitive impairment before developing
into late stage dementia or Alzheimer’s. For that reason, there is a natural ordering proper
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disease classification using variables which start with the control followed by mild cognitive
impairment to an official Alzheimer’s diagnosis among participants. Accordingly, this study
sought to find a model that took into consideration the ordinal property of the response variable
into account, and that is an ordinal LASSO logistic regression model.
Figures 12 and 13 depicts the coefficient entry path into the models by betas, lambda, and
steps for backward and forward selection method, respectively [35-36]. Figure 14, 16, and 18
presents the trends of the Bayesian Information Criterion (BIC) and Akaike Information
Criterion (AIC) over steps, lambda, and betas for backward selection. Likewise, figures 15, 17,
and 19 present the trends of both BIC and AIC over steps, lambda, and betas for forward
selection. Based on these plots, models 2 through 6 were determined to be indifferent and have
the lowest BIC and AIC values. Non-zero coefficients for the models used during these steps are
seen in Table 5.
At step one, the empty model was fitted. In step two, two and four predictors entered the
model in the backward and forward selection, respectively. Both supplementary motor and
putamen regions of the brain were good predictors at this step. The backward selection gradually
increased the number of predictors as the number of steps increased. In contrast to the forward
selection, the models at step 4-6 remained stable with the same nine predictors. Moreover,
certain brains regions were found to be consistently good predictors in both methods of selection.
These regions included: supplementary motor, the putamen, the pallidum, the cerebral, and the
vermis regions. These results are not in agreement with earlier studies and have not been
previous cited as brain regions which are typically associated with the disease. However, these
findings are congruent with the non-ordinal results presented earlier in this study.
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The different models’ sensitivity, specificity, and accuracy rates are displayed in Figure
20. These rates demonstrate the underperformance of these models. While MCI were accurately
predicted in all models, the models failed to predict both normal and AD classes. These rates
only improved with the increased BIC and AIC levels. More specifically, the accuracy rates
improved around the midpoint of BIC and AIC, or at step 25 and higher.

5. LIMITATIONS AND DIRECTION FOR THE FUTURE
Although two studies [20,21] documented lack of association between demographic
characteristics, several others found significant association between certain demographics and
Alzheimer’s disease. Among demographics found to be related to the disease are age [38],
gender [39], education [40], and race [41]. Although majority of these studies date back to
1980s, 1990s, and early 2000, we believe the decision to exclude these factors from the current
study limits the results and conclusion.
One of LASSO’s disadvantages is its inability to distinguish between correlated data.
With brain MRI unfortunately, all of the brain regions are somehow correlated. LASSO just
picks one over the other, indeed, we do not know which variable is chosen. Modeling with a
different constraining penalty may ameliorate this problem. Elastic net is a regularization
introduced to the model that uses a mix of L1 and L2 norms. It simultaneously shrinks the
coefficients and accomplishes sparse selection. This method could possibly be a better method to
answer the research question at hand.
As a final note, in the era of fast growing technology, the acquisition of brains images is
becoming readily available. At first glance, these images provide insight into the brain regions’
structure. These is images can further be scrutinized and transferred to pure data than can be
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further analyzed. Having prior set models for disease classification can help health providers
easily diagnose patients. It is therefore imperative to explore this field further.
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APPENDIX A: LIST OF VARIABLES
PRECENTL: Left Percentile
PRECENTR: Right Percentile
FRONTSUPL: Left Frontal Supplementary
FRONTSUPR: Right Frontal Supplementary
FRONTSORBL: Left Frontal sorbitol
FRONTSORBR: Right Frontal sorbitol
FRONTMIDL: Left Frontal Medial
FRONTMIDR: Right Frontal Medial
FRTMIDORBL: Left Frontal Medial Orbital
FRTMIDORBR: Right Frontal Medial Orbital
FRONTINOPL: Left Frontal Inferior Opercula
FRONTINOPR: Right Frontal Inferior Opercula
FRONTINTRL: Left Frontal Inferior
FRONTINTRR: Right Frontal Inferior
FRONTINOBL: Left Frontal Inferior Orbital
FRONTINOBR: Right Frontal Inferior Orbital
ROLANDOPL: Left Rolandic Operator
ROLANDOPR: Right Rolandic Operator
SUPMOTORL: Left Supplementary Motor
SUPMOTORR: Right Supplementary Motor
OLFACTL: left Olfactory
OLFACTR: Right Olfactory
FRONTSMEDL: Left Frontal Supplementary Medial
FRONTSMEDR: Right Supplementary Medial
FRTMEDORBL: Left Frontal Medial Orbital
FRTMEDORBR: Right Frontal Medial Orbital
RECTUSL: Left Rectus
RECTUSR: Right Rectus
INSULAL: Left Insula
INSULAR: Right Insula
CINGANTL: Left Cingulum Angular Bundle
CINGANTR: Right Cingulum Angular Bundle
CINGMIDL: Left Cingulum Medial
CINGMIDR: Right Cingulum Medial
CINGPOSTL: Left Cingulum Posterior
CINGPOSTR: Right Cingulum Posterior
HIPPL: Left Hippocampus
HIPPR: Right Hippocampus
PARAHIPPL: Left Parahippocampus
PARAHIPPR: Right Parahipocampus
AMYGDL: Left Amygdala
AMYGDR: Right Amygdala
CALCARINEL: Left Calcarine
CALCARINER: Right Calcarine
CUNEUSL: Left Cuneus
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CUNEUSR: Right Cuneus
LINGUALL: Left Lingual
LINGUALR: Right Lingual
OCCSUPL: Left Supplementary Occipital
OCCSUPR: Right Supplementary Occipital
OCCMIDL: left Occipital Medial
OCCMIDR: Right Occipital Medial
OCCINFL: Left Occipital Inferior
OCCINFR: Right Occipital Inferior
FUSIFORML: Left Fusiform
FUSIFORMR: Right Fusiform
POSTCENTL: Left Posterior Central
POSTCENTR: Right Posterior Central
PARIETSUPL: Left Supplementary Parietal
PARIETSURP: Right Supplementary Parietal
PARIETINFL: Left Inferior Parietal
PARIETINFR: Right Inferior Parietal
SUPRAMARGL: Left Supplementary amygdala
SUPRAMARGR: Right Supplementary amygdala
ANGULARL: Left Angular
ANGULARR: Right Angular
PRECUNEUSL: Left PreCuneus
PRECUNEUSR: Right PreCuneus
PARCENTLBL: Left Paracentral Lobe
PARCENTLBR: Right Paracentral Lobe
CAUDATEL: Left Caudate
CAUDATER: Right Caudate
PUTAMENL: Left Putamen
PUTAMENR: Right Putamen
PALLIDUML: Left Pallidum
PALLIDUMR: Right Pallidum
THALAMUSL: Left Thalamus
THALAMUSR: Right Thalamus
HESCHLL: Left Heschel
HESCHLR: Right Heschel
TEMPSUPL: Left Supplementary Temporal
TEMPSURP: Right Supplementary Temporal
TEMPPLSUPL: Left Supplementary Temporal Plane
TEMPPLSUPR: Right Supplementary Temporal Plane
TEMPMIDL: Left Medial Temporal
TEMPMIDR: Right Medial Temporal
TEMPPLMIDL: Left Medial Temporal Plane
TEMPPLMIDR: Right Medial Temporal Plane
TEMPINFL: Left Inferior Temporal
TEMPINFR: Right Inferior Temporal
CEREBCR1L: Left Cerebral Cortex Region 1
CEREBCR1R: Right Cerebral Cortex Region 1
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CEREBCR2L: Left Cerebral Cortex Region 2
CEREBCR2R: Right Cerebral Cortex Region 2
CEREBCR3L: Left Cerebral Cortex Region 3
CEREBCR3R: Right Cerebral Cortex Region 3
CEREB45L: Left Cerebral Region 4-5
CEREB45R: Right Cerebral Region 4-5
CEREB6L: Left Cerebral Region 6
CEREB6R: Right Cerebral Region 6
CEREB7BL: Left Cerebral Blood
CEREB7BR: Right Cerebral Blood
CEREB8L: Left Cerebral Region 8
CEREB8R: Right Cerebral Region 8
CEREB9L: Left Cerebral Region 9
CEREB9R: Right Cerebral Region 9
CEREB10L: Left Cerebral Region 10
CEREB10R: Right Cerebral Region 10
VERMIS12: Vermis Region 1-2
VERMIS3: Vermis Region 3
VERMIS45: Vermis Region 4-5
VERMIS6: Vermis Region 6
VERMIS7: Vermis Region 7
VERMIS8: Vermis Region 8
VERMIS10: Vermis Region 10
ETIV: Estimated Intracranial Volume
DXCURREN: Current Diagnosis (1: Normal, 2: MCI, 3: AD)
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APPENDIX B: TABLES
Table 1: Descriptive Statistics of the Participants
Characteristic
Age
Education
Male
Right-Handed
Marital Status
Married
Widowed
Divorced
Never Married
Unknown
Retired
Yes
No
Missing
Primary language
English
Spanish
Unknown

N(%)
75.10 (±6.72)
16 (14-18))
208 (58.26)
323 (90.48)
255 (74.34)
52 (15.16)
24 (7.0)
11 (3.21)
1 (0.29%)
288 (83.97)
34(9.91)
21 (6.12)
337 (98.25)
2 (0.58%)
28 (0.82)

Age: mean (±SD), Year of education: median (IQR)

Table 2: Non-Zero Coefficients Cross-Validation Multinomial LASSO – AD&MCI vs. Control
Control
Coefficient
FRONTINOPR
SUPMOTORL
CUNEUSR
PARIETSUPR
PARIETINFL
PUTAMENR
HESCHLR
TEMPPLMIDL
TEMPINFL
CEREBCR2L
CEREBCR2R
CEREB45L
CEREB7BR
CEREB10R
VERMIS12
VERMIS10

MCI
Coefficient
Estimates
4.4076812
2.2581351
-2.3267197
0.1030343
2.3798372
2.9849488
-0.2553623
0.1252874
3.8724262
0.5981673
2.2958389
1.0101785
0.2986538
-0.4135493
-1.7909975
-0.3605663

Coefficient
FRONTINOPL
RECTUSL
CINGMIDL
CINGPOSTR
AMYGDL
CALCARINER
OCCMIDR
OCCINFL
SUPRAMARGL
THALAMUSL
TEMPMIDL
CEREB3L
CEREB10L

AD
Coefficient
Estimates
5.2001940
4.4316612
0.6565016
-0.8786198
-0.3010206
1.7689149
-2.7842050
0.2076641
1.2655111
-0.2908878
0.6243081
-1.6049941
-0.6472638

Coefficient
FRONTSUPR
FRONTMIDR
FRTMIDORBR
FRTMEDORBR
OCCINFL
POSTCENTR
SUPRAMARGR
PARCENTLBL
PARCENTLBR
THALAMUSL
HESCHLR
CEREB7BR
CEREB10R
VERMIS6
ETIV

Coefficient
Estimates
1.2870474
3.3329974
1.6357613
4.0945468
-2.0094674
-2.9393642
-0.3856534
-1.5763218
-1.2712380
0.6101122
0.7034065
-0.2797097
0.5352596
1.0312296
-0.3119901
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Table 3: Cross-Validation Coefficients Under Different Lambda Values.
Class

𝝀𝝀𝟏𝟏

𝝀𝝀𝟐𝟐

𝝀𝝀𝟓𝟓

𝝀𝝀𝟕𝟕

𝝀𝝀𝟏𝟏𝟏𝟏

Binomial (AD
vs. Control)

None

PARCENTLBR
PUTAMENR

SUPMOTORR
FRTMEDORBR
POSTCENTR
PARCENTLBL
PARCENTLBR
PUTAMENR
CEREB7BR
VERMIS12

SUPMOTORL
FRTMEDORBR
OCCINFL
POSTCENTR
PARCENTLBR
PUTAMENR
PALLIDUML
CEREB7BR
CEREB10R
VERMIS12
VERMIS6

FRONTSURP
FRTMIDORBR
FRONTINOPR
SUPMOTORL
FRTMEDORBR
OCCINFR
POSTCENTR
PARCENTLBL
PARCENTLBR
PUAMENR
HESCHLR
TEMPPLMIDL
TEMPINFL
CEREBCR2L
CEREBCR2R
CEREB7BR
CEREB10R
VERMIS45
VERMIS6

Binomial
(AD&MCI vs.
Control)

None

PUTAMENR

SUPMOTORL
PUTAMENR
VERMIS12

FRONTINOPL
SUPMPTPRL
RECTUSL
PUTAMENR
CEREBCR2R
CEREB7BR
VERMIS12

FRONTINOPL
FRONTINOPR
SUPMOTORL
RECTUSL
CINGANTR
CUNEUSR
PARIETINFL
PUTAMENR
HESCHLR
TEMPINFL
CEREBCR2R
CEREB7BR
VERMIS12

Binomial (AD
vs.
MCI&Control)

None

PARCENTLBL

FRTMEDORBR
POSTCENTR
PARCENTLBL
PARCENTLBR
CEREB8R

FRTMEDORBR
OCCINFL
POSTCENTR
SUPRAMARGR
PARCENTLBL
PARCENTLBR
CEREB7BR
VERMIS12
VERMIS6

FRONTMIDR
FRIMIDORBR
FRTMEDORBR
OCCINFR
POSTCENTR
SUPRAMARGR
PARCENTLBL
PARCENTLBR
THALAMUSL
HESCHLR
TEMPSURL
CEREB7BR
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CEREB10R
VERMIS12
VERMIS6
ETIV
Multinomial
(AD vs. MCI
vs. Control)
Control

None

PUTAMENR

SUPMOTORL
PUTAMENR
CEREBCR2R

SUPMOTORL
PUTAMENR
CEREBCR2R
CEREB5BR
VERMIS12

FRONTINOPR
SUPMOTORL
CUNEUSR
PARIETINFL
PUTAMENR
TEMPINFL
CEREBCR2R
CEREBCR7R
VERMIS12
VERMIS10

MCI

None

FRONTINOPL

FRONTINOPL

FRONTINOPL
RECTUSL
SUPRAMARGL
CEREB3L

FRONTINOPL
RECTUSR
CALCARINER
OCCMIDR
SUPRAMARGR
CEREB3R

AD

None

None

FRTMEDORBR
PARCNTLBL

FRTMEDORBR
PARCENTLBL
PARCENTLBR

FRONTMIDR
FRTMIDORBR
FRTMEDORBR
OCCINFL
POSTCENTR
PARCENTLBL
PARCENTLBR
THALAMUSL
HESCHLR
CEREB7BR
CEREB10R
VERMIS6

FRONTINOPL
PUTAMENR

FRONTINOPL
SUPMOTORL
FRTMEDORBR
RECTUSL
PARCENTLBL
PUTAMENR
CEREBCR2R
CEREB7BR
VERMIS12

FRONTINOPL
FRONTINOPR
SUPMOTORL
FRTMEDORBR
RECTUSL
SUPRAMARGL
PARCENTLBL
PARCENTLBR
PUTAMENR
CEREBCR2R
CEREB3L
CEREB7BR

FRONTMIDR
FRTMIDORBR
FRONTINOPL
FRONTINOPR
SUPMOTORL
FRTMEDORBR
RECTUSL
CALCARINER
CUNEUSR
OCCMIDR
OCCINFL
POSTCENTR

GroupedMultinomial
(AD vs. MCI
vs. Control)
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VERMIS12

PARIETINFL
SUPRAMARGL
PARCENTLBL
PARCENTLBR
PUTAMENR
THALAMUSL
HESCHLR
TEMPINFL
CEREBCR2R
CEREB3L
CEREB45L
CEREB7BR
CEREB10R
VERMIS12
VERMIS6
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Table 4: Predictor of Cross-Validated Models Based on Prediction Error Suggested Lambda
Values.
Class
Binomial (AD&MCI vs.
Control)

Binomial (AD vs.
MCI&Control)

Grouped-Multinomial (AD
vs. MCI vs. Control)

Penalty
Value (s)
s = 0.03

Non-Zero Coefficients

s = 0.04

SUPMOTORL, PUTAMENR, VERMIS12

s = 0.05

FRONTINOPL, SUPMOTORL, FRTMEDORBR, RECTUSL, PARCENTLBL,
PUTAMENR, CEREBCR2R, CEREB7BR, VERMIS12

s = 0.055

FRONTINOPL, SUPMOTORL, PARACENLBL, PUTAMENL, VERMIS12

s = 0.06

FRONTINOPL, SUPMOTORL, PARCENTLBL, PUTAMENR

s = 0.07

FRONTINOPL, PUTAMENR

s = 0.015

FRONTSUPR, FRONTMIDR, FRTMIDORBR, FRONTINOPL, FRONTSMEDL,
FRTMEDORBR, RECTUSL, OCCSUPR, OCCINFL, POSTCENTR, SUPRAMARGR,
PARCENTLBL, PARCENTLBR, CAUDATEL, PALLIDUML, THALAMUSL,
HESCHLR, TEMPSUPL, TEMPPLMIDL, CEREB3L, CEREB7BR, CEREB10R,
VERMIS12, VERMIS6, VERMIS8, ETIV

s = 0.03

FRTMEDORBR, OCCINFL, POSTCENTR, SUPRAMARGR, PARCENTLBL,
PARCENTLBR, CEREB7BR, VERMIS12, VERMIS6

s = 0.02

FRONTSUPR, FRONTMIDR, FRTMIDORBR, FRONTINOPL, FRONTINOPR,
FRONTINOBR, SUPMOTORL, FRTMEDORBR, RECUSL, CINGANTR,
CINGMIDL, CINGPOSTR, AMYGDL, CALCARINER, CUNEUSR, OCCMIDR,
OCCINFL, POSTCENTR, PARIETSUPR, PARITINFL, SUPRAMARGL,
SUPRAMARGR, PARCENTLBL, PARCENTLBR, CAUDATEL, PUTAMENR,
THALAMUSL, HESCHLR, TEMPSUPL, TEMPMIDL, TEMPPLMIDL, TEMPINFL,
CEREBCR2L, CEREBCR2R, CEREB3L, CEREB3R, CEREB45L, CEREB6L,
CEREB7BR, CEREB10L, CEREB10R, VERMIS12, VERMIS6, VERMIS8,
VERMIS10, ETIV

FRONTINOPL, SUPMOTORL, RECTUSL, CUNEUSR, PARIETINFL,
PUTALMENR, HESCHLR, CEREBCR2R, CEREB7BR, VERMIS12
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Table 5: Non-Zero Coefficients for Backward and Forward Models.
Step 1

Step 2

Step 3

Step 4
Backward Models

None

SUPMOTORL
PUTAMENR

SUPMOTORL
PUTAMENR
VERMIS12

None

SUPMOTORL
PARCENTLBL
PARCENTLBR
VERMIS12

SUPMOTORL
POSTCENR
PARCENTLBL
PARCENTLBR
PUTAMENR
PALLIDUML
CEREB7BR
VERMIS12

SUPMOTORL
PUTAMENR
CEREB7BR
VERMIS12

Step 5

Step 6

SUPMOTORL
FREMEDORBR
PUTAMENR
CEREB7BR
VERMIS12

SUPMOTORL
FREMEDORBR
PUTAMENR
PALLIDUML
CEREB7BR
VERMIS12

SUPMOTORL
FRTMEDORBR
POSTCENR
PARCENTLBL
PARCENTLBR
PUTAMENR
PALLIDUML
CEREB7BR
VERMIS12

SUPMOTORL
FRTMEDORBR
POSTCENR
PARCENTLBL
PARCENTLBR
PUTAMENR
PALLIDUML
CEREB7BR
VERMIS12

Forward Models
SUPMOTORL
FRTMEDORBR
POSTCENR
PARCENTLBL
PARCENTLBR
PUTAMENR
PALLIDUML
CEREB7BR
VERMIS12
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APPENDIX C: FIGURES
Figure 1: Trace Plot of Coefficients Fit by Binomial LASSO – AD vs. Control (Left: Coefficients are
plotted against the Fraction Deviance Explained; Right: coefficients are plotted against the L1 Norm)

Figure 2: Trace Plot of Coefficients Fit by Binomial LASSO – AD and MCI vs. Control (Left:
Coefficients are plotted against the Fraction Deviance Explained; Right: coefficients are plotted against
the L1 Norm)
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Figure 3: Trace Plot of Coefficients Fit by Binomial LASSO – AD vs. MCI and Control (Left:
Coefficients are plotted against the Fraction Deviance Explained; Right: coefficients are plotted against
the L1 Norm)

Figure 4: Coefficients Fit by Multinomial LASSO – AD vs. MCI vs. Control (Left: Coefficients are
plotted against the Fraction Deviance Explained; Right: coefficients are plotted against the L1 Norm)
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Figure 5: Coefficients Fit by Grouped Multinomial LASSO – AD vs. MCI vs. Control (Left: Coefficients
are plotted against the Fraction Deviance Explained; Right: coefficients are plotted against the L1 Norm)

Figure 6: Specificity, Sensitivity, and Accuracy Rates of LASSO Fitted Model Prediction
AD vs. C (Greens), AD vs. MCI&C (Blues), AD&MCI vs. C (Yellows), AD vs. MCI. C (Peach), and Grouped AD vs. MCI
vs. C (Purples)
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Figure 7: Cross-Validation Error (& Mean Error – Left) Curve for Binomial LASSO – AD vs.
Control (𝜆𝜆𝑚𝑚𝑚𝑚𝑚𝑚 = 𝜆𝜆1𝑠𝑠𝑠𝑠 = 0.07003043 with zero coefficients)

Figure 8: Cross-Validation Error (& Mean Error – Left) Curve for Binomial LASSO –
AD&MCI vs. Control (𝜆𝜆𝑚𝑚𝑚𝑚𝑚𝑚 = 𝜆𝜆1𝑠𝑠𝑠𝑠 = 0.05800169 with zero coefficients)
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Figure 9: Cross-Validation Error (& Mean Error – Left) Curve for Binomial LASSO – AD vs.
MCI&Control (𝜆𝜆𝑚𝑚𝑚𝑚𝑚𝑚 = 𝜆𝜆1𝑠𝑠𝑠𝑠 = 0.0501518 with zero coefficients)

Figure 10: Cross-Validation Error (& Mean Error – Left) Curve for Multinomial LASSO – AD
vs MCI vs. Control (𝜆𝜆𝑚𝑚𝑚𝑚𝑚𝑚 = 0.01899294, 𝜆𝜆1𝑠𝑠𝑠𝑠 = 0.05800169, coefficients entering the model listed
on Table 1)
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Figure 11: Cross-Validation Error (& Mean Error – Left) Curve for Grouped Multinomial
LASSO – AD vs MCI vs. Control (𝜆𝜆𝑚𝑚𝑚𝑚𝑚𝑚 = 𝜆𝜆1𝑠𝑠𝑠𝑠 = 0.0715801 with no coefficients)
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Figure 12: Ordinal LASSO Logistic Regression Coefficient Path by Betas (a) Lambda (b), and
Steps (c) for Backward Model
(a)

(b)

(c)
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Figure 13: Ordinal LASSO Logistic Regression Coefficient Path by Betas (a) Lambda (b), and
Steps (c) for Forward Model
(a)

(b)

(c)

35

Figure 14: Ordinal LASSO Backward Model’s BIC (a), and AIC (a) by Steps.
(a)

(b)
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Figure 15: Ordinal LASSO Forward Model’s BIC (a), and AIC (a) by Steps.
(a)

(b)
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Figure 16: Ordinal LASSO Backward Model’s BIC (a), and AIC (a) by Lambda Values.
(a)

(b)
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Figure 17: Ordinal LASSO Forward Model’s BIC (a), and AIC (a) by Lambda Values.
(a)

(b)
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Figure 18: Ordinal LASSO Backward Model’s BIC (a), and AIC (a) by Beta
(a)

(b)
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Figure 19: Ordinal LASSO Forward Model’s BIC (a), and AIC (a) by Beta
(a)

(b)

Figure 20: Sensitivity, Specificity, and Accuracy Rates for Backward and Forward Ordinal
Models by Steps.
Backward Model (Blues) Forward Model (Greens)
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